Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04879043 · ClinicalTrials.gov registry record · Phase 1

Study to Assess Safety of HDP-101 in Patients With Relapsed Refractory Multiple Myeloma

A Phase 1 study of Multiple Myeloma and Plasma Cell Disorder, sponsored by Heidelberg Pharma.

Recruiting
Registry status
Phase 1
Development phase
78
Enrollment target
16
Study locations

NCT04879043: Recruiting Phase 1 study of Multiple Myeloma and Plasma Cell Disorder, sponsored by Heidelberg Pharma.

NCT04879043 is a Phase 1 study of Multiple Myeloma and Plasma Cell Disorder that is actively recruiting participants, run by Heidelberg Pharma. The registered enrollment target is 78 participants, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (86% lower). The trial reports 16 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04879043, a Phase 1 study of Multiple Myeloma and Plasma Cell Disorder, is actively recruiting participants, sponsored by Heidelberg Pharma.

RECRUITING
Registry status
Phase 1
Development phase
78 participants
Enrollment target
16
Study locations

Study Summary

This study will assess the safety, tolerability, pharmacokinetics (PK) and the therapeutic potential of HDP-101 in patients with plasma cell disorders including multiple myeloma.

Conditions Studied

Multiple Myeloma Plasma Cell Disorder

Interventions

  • DRUG HDP-101

Study Locations (16)

Other

  • Charité - Campus Benjamin Franklin Med. Klinik m.S. Hämatologie, Onkologie - Berlin
  • Klinikum Chemnitz gGmbH, Klinik f. Innere Medizin III - Chemnitz
  • Universitätsklinikum Köln - Cologne
  • Asklepios Klinik Altona, Haematologie und internistische Onkologie - Hamburg
  • Universitätsklinikum Heidelberg - Heidelberg
  • Universitätsklinikum Schleswig-Holstein - Kiel
  • UKSH Campus Lübeck Klinik für Hämatologie und Onkologie - Lübeck
  • Universitätsklinikum Mainz - Mainz
  • Semmelweis University, Belgyogyaszati es Onkologiai Klinika - Budapest
  • National Institute of Oncology, Department of Oncological Internal Medicine - Budapest
  • Pratia Onkologia Katowice - Katowice
  • Wojewodzkie Wielospecjalistyczne Centrum Onkologii i Traumatologii im. M. Kopernika w Lodzi - Lodz
  • Szpital Wojewodzki w Opolu - Opole

Georgia

  • Winship Cancer Institute of Emory University - Atlanta

New York

  • Mount Sinai, The Tisch Cancer Instutute - New York

Texas

  • MD Anderson Cancer Center - Houston

Trial Details

FieldValue
Enrollment Target 78 participants
Start Date 2022-02-07
Est. Completion 2026-05
Phase Phase 1

Sponsor

Heidelberg Pharma

5 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT04879043

The ClinicalTrials.gov registry entry for NCT04879043 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 78 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (86% lower). The listed sponsor is Heidelberg Pharma, which has 5 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Multiple Myeloma appearing as the primary indexed condition, and to 1 intervention - of which HDP-101 is the first listed.

NCT04879043 reports 16 study locations spanning 4 distinct geographic areas - top geographies include Other, Georgia, New York.

Frequently Asked Questions

What is clinical trial NCT04879043 about?

NCT04879043 is a clinical study titled "Study to Assess Safety of HDP-101 in Patients With Relapsed Refractory Multiple Myeloma". This study will assess the safety, tolerability, pharmacokinetics (PK) and the therapeutic potential of HDP-101 in patients with plasma cell disorders including multiple myeloma.

What is the current status of trial NCT04879043?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 78 participants. The study started on 2022-02-07. Estimated completion is 2026-05.

What conditions does trial NCT04879043 study?

This clinical trial studies the following conditions: Multiple Myeloma, Plasma Cell Disorder.

What interventions are being tested in trial NCT04879043?

The interventions under investigation include: HDP-101 (DRUG).

Who is sponsoring clinical trial NCT04879043?

This trial is sponsored by Heidelberg Pharma, which has 5 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04879043 being conducted?

This trial has 16 study locations across Georgia, New York, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Multiple Myeloma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Multiple Myeloma

All registered trials for this condition

Plasma Cell Disorder

All registered trials for this condition

Georgia

All trials with a study site in Georgia

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Related

Compare this shortlist side-by-side

Read our methodology - how this data is sourced, computed, and verified.
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.